Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ACP1 | P24666 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4832314 | 0.97 | TSHR (0.70) | TSHRHTTLMNAABCB1ABCG2 | |
| SCHEMBL4633382 | 0.93 | TSHR (0.62) | TSHRHTTLMNAABCB1ABCG2 | |
| SCHEMBL14306234 | 0.90 | TSHR (0.57) | TSHRHTTLMNAABCB1ABCG2 | |
| SCHEMBL4633373 | 0.90 | TSHR (0.64) | TSHRHTTLMNAABCB1ABCG2 | |
| SCHEMBL4832182 | 0.90 | TSHR (0.58) | TSHRHTTLMNAABCB1ABCG2 | |
| SCHEMBL4834511 | 0.89 | TSHR (0.56) | TSHRHTTLMNAABCB1ABCG2 | |
| SCHEMBL4828164 | 0.89 | TSHR (0.56) | TSHRHTTLMNAABCB1ABCG2 | |
| SCHEMBL4829830 | 0.88 | TSHR (0.54) | TSHRHTTLMNASCN8AGAA | |
| SCHEMBL4834583 | 0.87 | TSHR (0.61) | TSHRHTTLMNAABCB1ABCG2 | |
| SCHEMBL4832413 | 0.86 | TSHR (0.66) | TSHRHTTLMNAABCB1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320989-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320989-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320989-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2008-01-03 | — | — | US | disclosed |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2008-01-03 | — | — | US | disclosed |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2008-01-03 | — | — | US | disclosed |
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | TSHR 1103/4885HTT 1829/4885LMNA 3004/4885 |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | TSHR 1103/4885HTT 1829/4885LMNA 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.